Form 4 for EW Edwards Lifesciences
Accepted 2024-05-09 00:00:00 ET · period of report 2024-05-07 · accession 0001225208-24-005882 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-09 | 2024-05-07 | EW | Szyman Catherine M. | CVP, Critical Care | F - Tax | $85.09 | -609 | 77.0K | -0.8% | -$51.8K | |
| 2024-05-09 | 2024-05-07 | EW | Szyman Catherine M. | CVP, Critical Care | A - Grant | $0.00 | +32.0K | 77.6K | +70% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-07 | F | D | 609 | $85.09 | 76,992.44 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-07 | A | A | 32,025 | $0.00 | 77,601.44 | D | — | — | (F1) These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |